date: 2021-09-26T16:11:32Z
pdf:PDFVersion: 1.4
pdf:docinfo:title: Addressing the ?hypoxia paradox? in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues
xmp:CreatorTool: Adobe InDesign 15.0 (Windows)
access_permission:can_print_degraded: true
subject: Molecular Medicine, https://doi.org/10.1186/s10020-021-00381-5
pdfa:PDFVersion: A-2b
xmpMM:History:Action: converted
language: en-US
dc:format: application/pdf; version=1.4
pdf:docinfo:custom:robots: noindex
pdf:docinfo:creator_tool: Adobe InDesign 15.0 (Windows)
access_permission:fill_in_form: true
xmpMM:History:When: 2021-09-21T06:43:21Z
pdf:encrypted: false
dc:title: Addressing the ?hypoxia paradox? in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues
modified: 2021-09-26T16:11:32Z
cp:subject: Molecular Medicine, https://doi.org/10.1186/s10020-021-00381-5
xmpMM:History:SoftwareAgent: pdfToolbox
pdf:docinfo:custom:CrossMarkDomains[1]: springer.com
robots: noindex
pdf:docinfo:subject: Molecular Medicine, https://doi.org/10.1186/s10020-021-00381-5
xmpMM:History:InstanceID: uuid:df3ce8a5-1229-4375-b475-12cd5ab4c9e9
pdf:docinfo:creator:  Martin Begemann
meta:author:  Oliver Gross
trapped: False
meta:creation-date: 2021-09-21T05:11:47Z
pdf:docinfo:custom:CrossmarkMajorVersionDate: 2010-04-23
created: 2021-09-21T05:11:47Z
access_permission:extract_for_accessibility: true
Creation-Date: 2021-09-21T05:11:47Z
pdfaid:part: 2
pdf:docinfo:custom:CrossMarkDomains[2]: springerlink.com
pdf:docinfo:custom:doi: 10.1186/s10020-021-00381-5
pdf:docinfo:custom:CrossmarkDomainExclusive: true
Author:  Oliver Gross
producer: Adobe PDF Library 15.0; modified using iText® 5.3.5 ©2000-2012 1T3XT BVBA (SPRINGER SBM; licensed version)
CrossmarkDomainExclusive: true
pdf:docinfo:producer: Adobe PDF Library 15.0; modified using iText® 5.3.5 ©2000-2012 1T3XT BVBA (SPRINGER SBM; licensed version)
doi: 10.1186/s10020-021-00381-5
pdf:unmappedUnicodeCharsPerPage: 0
dc:description: Molecular Medicine, https://doi.org/10.1186/s10020-021-00381-5
Keywords: Recombinant human EPO;Darbepoetin;Neuroprotection;Treatment;Signaling;Critical care;Outcome
access_permission:modify_annotations: true
dc:creator:  Oliver Gross
description: Molecular Medicine, https://doi.org/10.1186/s10020-021-00381-5
dcterms:created: 2021-09-21T05:11:47Z
Last-Modified: 2021-09-26T16:11:32Z
dcterms:modified: 2021-09-26T16:11:32Z
title: Addressing the ?hypoxia paradox? in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues
xmpMM:DocumentID: uuid:df3ce8a5-1229-4375-b475-12cd5ab4c9e9
Last-Save-Date: 2021-09-26T16:11:32Z
CrossMarkDomains[1]: springer.com
pdf:docinfo:keywords: Recombinant human EPO;Darbepoetin;Neuroprotection;Treatment;Signaling;Critical care;Outcome
pdf:docinfo:modified: 2021-09-26T16:11:32Z
meta:save-date: 2021-09-26T16:11:32Z
Content-Type: application/pdf
X-Parsed-By: org.apache.tika.parser.DefaultParser
creator:  Oliver Gross
pdfaid:conformance: B
dc:language: en-US
dc:subject: Recombinant human EPO;Darbepoetin;Neuroprotection;Treatment;Signaling;Critical care;Outcome
access_permission:assemble_document: true
xmpTPg:NPages: 11
pdf:charsPerPage: 4211
access_permission:extract_content: true
access_permission:can_print: true
pdf:docinfo:trapped: False
CrossMarkDomains[2]: springerlink.com
meta:keyword: Recombinant human EPO;Darbepoetin;Neuroprotection;Treatment;Signaling;Critical care;Outcome
access_permission:can_modify: true
pdf:docinfo:created: 2021-09-21T05:11:47Z
CrossmarkMajorVersionDate: 2010-04-23